JANX at a glance
Janux Therapeutics, Inc. (JANX, SEC CIK 1817713) filed its latest 10-K annual report on February 26, 2026, a 10-Q quarterly report on August 6, 2026, an 8-K current report on August 6, 2026 and Form 4 insider filings as recently as July 31, 2026. SignalX summarizes each filing with AI and tracks the company's insider trades and institutional holders.
- For the fiscal year ended December 31, 2025 (FY2025), Janux Therapeutics, Inc. (JANX) reported revenue of $10.0 million (down 5.6% from FY2024) and a net loss of $113.6 million. Diluted EPS was -$1.83.
- As of June 30, 2026, 25 institutional investment managers tracked by SignalX reported holding Janux Therapeutics, Inc. (JANX) shares worth $353.5 million in 13F-HR filings.
Source: SEC EDGAR (XBRL financial data, 13F-HR and Form 4 filings).
- Revenue · FY2025
- $10.0M
- −5.6% vs prior year
- Insiders · 90 days
- 0 buys · 0 sells
- No open-market trades
- 13F holders
- 25 funds
- $353.5M · +1 vs prior quarter
- Latest 8-K
- Aug 6, 2026
- Item 2.02
AI 10-Q Quarterly Report Analysis
Latest 10-Q, quarter ended Jun 30, 2026
Management Discussion & Analysis
- Collaboration revenue $10.3M, up $10.3M YoY from $0, driven by BMS Agreement research services
- Net loss $22.0M vs $33.9M YoY; operating margin not disclosed
- R&D expense $31.0M, down $3.7M YoY; highest program spend JANX007 at $6.2M
- Cash, equivalents, restricted cash and short-term investments $971.7M as of June 30, 2026
- Operating cash flow $0.1M vs $(40.8)M YoY; $30.0M net short-term investment purchases
- Existing liquidity expected to fund operations and capital expenditures through at least the next 12 months; continued losses anticipated
Risk Factors
- April 2026 JANX008 discontinuation after Phase 1a, reflecting insufficient activity versus other pipeline programs
- Cash, equivalents and short-term investments $970.9 million at June 30, 2026, funding operations for at least 12 months
- Additional capital required for regulatory approval and commercialization, creating dilution or potential program reductions
- Data-privacy noncompliance exposure, including regulatory actions, class claims, mass arbitration, fines and operational disruption
- Novel immuno-oncology technologies face rapid competitor innovation and limited clinical data for JANX007, JANX011 and JANX014
AI summary of the JANX 10-Q filed . Generated from the filing text; verify against the original.View on SEC EDGAR10-K vs 10-Q vs 8-K
AI 8-K Current Report Analysis
The most recent material events, by 8-K item
Item EX-99.1: Item EX-99.1
- Q2 collaboration revenue $10.3M; net loss narrowed to $22.0M from $33.9M year over year
- Cash, equivalents and short-term investments $970.9M, supporting multiple clinical programs
Item 2.02: Results of Operations and Financial Condition
- Q2 and first-half 2026 financial results announced for periods ended June 30, 2026
- Press release attached as Exhibit 99.1, containing the substantive financial details
Item 8.01: Other Events
- Chief Medical Officer William Go, M.D., Ph.D. departed June 23, 2026, in a termination without “Cause”
- Successor search underway, with existing clinical leadership assuming interim responsibilities
Item 5.07: Submission of Matters to a Vote of Security Holders
- 88.2% of outstanding shares represented at the June 11 annual meeting, supporting strong shareholder participation
- Natasha Hernday and Eric Dobmeier elected as Class II directors through the 2029 annual meeting
AI summaries of JANX 8-K current reports filed with the SEC. What 8-K item codes mean
SignalX for JANX
Don't miss the next JANX filing
- Alerts as it files. A push when JANX files an 8-K or an insider trades.
- Fund moves. Which tracked funds opened, added or cut JANX, by share count.
- Ask anything. An AI agent that reads every JANX filing and answers with sources.
JANX alerts on your phone. Follow it in the SignalX Android app.
Recent Insider Transactions (Form 4)
Latest reported trades by officers, directors and 10% owners
| Insider | Type | Date | Shares | Price |
|---|---|---|---|---|
| Campbell David Alan | G | Jul 31, 2026 | 123,840 | - |
| Campbell David Alan | M | Jul 8, 2026 | 7,000 | - |
| Campbell David Alan | M | Jul 8, 2026 | 7,000 | $4.21 |
| Kung Winston | A | Jun 11, 2026 | 15,500 | - |
| CAPPS VICKIE L | A | Jun 11, 2026 | 5,500 | - |
| CAPPS VICKIE L | A | Jun 11, 2026 | 15,500 | - |
| Simson Jake | A | Jun 11, 2026 | 5,500 | - |
| Barrett Ronald W | A | Jun 11, 2026 | 15,500 | - |
Financial SummaryXBRL
| Metric | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
| Profitability | |||
| Revenue | - | $10.6M | $10.0M |
| Operating Income | - | -$98.8M | -$157.7M |
| Net Income | -$58.3M | -$69.0M | -$113.6M |
| Op. Margin | - | -933.6% | -1576.7% |
| Net Margin | - | -651.6% | -1136.3% |
| Balance Sheet | |||
| Total Assets | $380.4M | $1.1B | $1.0B |
| Equity | - | $1.0B | $956.8M |
| ROE | - | -6.7% | -11.9% |
| Per Share | |||
| EPS | $-1.32 | $-1.28 | $-1.83 |
| Cash Flow | |||
| Operating CF | - | -$43.8M | -$82.2M |
| CapEx | $1.9M | $359K | $1.0M |
Source: XBRL data in Janux Therapeutics, Inc. (JANX)'s 10-K filings on SEC EDGAR, in USD. Compare across companies →
13F Fund Holdings: Quarterly Trend
Latest: Q2 2026Aggregate JANX share value held by 13F filers tracked by SignalX, by quarter.
Quarterly totals table
| Quarter | Funds | Total value |
|---|---|---|
| Q2 2026 | 25 | $353.5M |
| Q1 2026 | 24 | $245.0M |
| Q4 2025 | 20 | $283.1M |
| Q3 2025 | 22 | $571.3M |
| Q2 2025 | 23 | $532.7M |
| Q1 2025 | 18 | $457.9M |
| Q4 2024 | 15 | $796.6M |
| Q3 2024 | 13 | $136.8M |
- Two Sigma Investments+1.09M (+940%)
- D.E. Shaw & Co+998.1K (+1014%)
- Citadel Advisors LLC+848.6K (+241%)
- BlackRock+701.4K (+13%)
- State Street Corp+540.9K (+22%)
- FMR LLC (Fidelity)−122.9K (-5%)
- JPMorgan Chase & Co−50.7K (-22%)
- AQR Capital Management+108.1K
- Allstate+18.5K
Source: 13F-HR filings on SEC EDGAR (aggregated from 160 fund-quarter rows). Reflects only 13F filers tracked by SignalX, not the full institutional ownership universe. How 13F filings work
JANX filing archive
AI analysis pages for each 10-K, 10-Q and 8-K
10-Q quarterly reports
Latest 2026 SEC Filings: 10-K, 10-Q, 8-K & Form 4
| Form | Filing date | Period | Analysis | SEC |
|---|---|---|---|---|
| 8-K | Aug 6, 2026 | - | Analysis | - |
| 10-Q | Aug 6, 2026 | Jun 30, 2026 | Analysis | |
| 4 | Jul 31, 2026 | - | - | - |
| 4 | Jul 10, 2026 | - | - | - |
| 8-K | Jun 23, 2026 | - | Analysis | - |
| 4 | Jun 12, 2026 | - | - | - |
| 4 | Jun 12, 2026 | - | - | - |
| 4 | Jun 12, 2026 | - | - | - |
| 4 | Jun 12, 2026 | - | - | - |
| 8-K | Jun 12, 2026 | - | Analysis | - |
| 4 | Jun 12, 2026 | - | - | - |
| 4 | Jun 12, 2026 | - | - | - |
| 4 | Jun 12, 2026 | - | - | - |
| 4 | Jun 4, 2026 | - | - | |
| 4 | May 13, 2026 | - | - | |
| SC 13G | May 12, 2026 | - | - | |
| 10-Q | May 7, 2026 | Mar 31, 2026 | Analysis | |
| 8-K | May 7, 2026 | - | Analysis | |
| SC 13G | Apr 29, 2026 | - | - | |
| SC 13G | Apr 29, 2026 | - | - | |
| 8-K | Apr 28, 2026 | - | Analysis | - |
| 8-K | Feb 26, 2026 | - | Analysis | - |
| 10-K | Feb 26, 2026 | Dec 31, 2025 | - | |
| SC 13G | Feb 9, 2026 | - | - | |
| SC 13G | Feb 6, 2026 | - | - |
Related Health Care companies
- AARD · Aardvark Therapeutics, Inc.Pharmaceutical Preparations
- ABT · Abbott LaboratoriesPharmaceutical Preparations
- ABBV · AbbVie IncPharmaceutical Preparations
- ABEO · ABEONA THERAPEUTICS INC.Pharmaceutical Preparations
- ACAD · ACADIA PHARMACEUTICALS INCPharmaceutical Preparations
- ACRS · Aclaris Therapeutics, Inc.Pharmaceutical Preparations
- ACTU · ACTUATE THERAPEUTICS, INC.Pharmaceutical Preparations
- ADCT · ADC Therapeutics SAPharmaceutical Preparations
JANX SEC filings: frequently asked questions
Which institutions hold JANX stock?
As of June 30, 2026, the largest Janux Therapeutics, Inc. (JANX) holders among the 13F filers tracked by SignalX were BlackRock ($94.2 million), State Street Corp ($46.2 million), FMR LLC (Fidelity) ($37.1 million), Vanguard Capital Management LLC ($28.5 million), Vanguard Portfolio Management LLC ($20.4 million). 13F-HR reports are filed up to 45 days after each quarter ends.
What was JANX's revenue in fiscal year 2025?
For the fiscal year ended December 31, 2025 (FY2025), Janux Therapeutics, Inc. (JANX) reported revenue of $10.0 million (down 5.6% from FY2024) and a net loss of $113.6 million. Diluted EPS was -$1.83. The figures come from the XBRL data in the 10-K.
What did JANX report in its latest 8-K?
Janux Therapeutics, Inc. (JANX) filed an 8-K on August 6, 2026 reporting Item 2.02 (Results of Operations and Financial Condition). Q2 collaboration revenue $10.3M; net loss narrowed to $22.0M from $33.9M year over year.
What are the latest JANX SEC filings?
Janux Therapeutics, Inc. (JANX) filed its latest 10-K annual report on February 26, 2026, a 10-Q quarterly report on August 6, 2026, an 8-K current report on August 6, 2026 and a Form 4 insider filing on July 31, 2026.
What is JANX's SEC CIK number?
Janux Therapeutics, Inc. (JANX)'s SEC Central Index Key (CIK) is 1817713. EDGAR lists every JANX filing under that number.
Ask anything about JANX
The research agent reads JANX's filings, financials, insider trades and 13F holders, then answers with sources.